Abstract:Aim: To observe the therapeutic efficacy and prognostic factors that influence survival rates in non-small cell lung cancer (NSCLC) patients with multiple brain metastases (BMs), (more than three and less than ten).Methods: Retrospective analyses were conducted on the clinical data of 209 NSCLC patients with multiple BMs and were admitted to our hospital between March 2007 and November 2012. All BM patients received whole-brain radiotherapy. Two hundred patients received combined chemotherapy during the treatment process; 99 received targeted drug therapy; and nine got only symptomatic and supportive treatment. Survival time was defined as the period from the start of BM therapy to the patient's death or end of the follow-up period. The Kaplan-Meier method was used to calculate the median survival time, and the 6-month, 1-, and 2-year cumulative survival rates, as well as to plot the survival curves. The patients' cultural background included their socioeconomic status, level of education, their understanding of the disease, and the degree of care and support they received from their family members. Log-rank test was employed to test the differences in the survival rates between the subgroups. Cox multivariate regression analyses were used to analyze the various factors influencing the prognoses of NSCLC with multiple BMs.Results: The follow-up duration was between 1 and 87 months. The median survival time for all BM patients was 12.1 months (95% confidence interval 9.37-14.83). The 6-month, 1-, and 2-year cumulative survival rates were 80%, 50.2%, and 10.7%, respectively. Univariate analyses revealed that the independent factors influencing survival prognoses included Karnofsky Performance Status score, control of the primary lung tumor, interval between the confirmed diagnoses of lung cancer and BM, presence of extracranial metastasis, number of chemotherapy cycles undergone, Graded Prognostic Assessment class, administration of combined targeted drug therapy, the pathological type, and the cultural backgrounds of the patients. Multivariate analyses indicated that the number of chemotherapy cycles, administration of combined drug therapy, and patients' cultural background were key independent factors influencing survival prognoses.Conclusion: Active treatment of NSCLC with multiple BMs was beneficial, and the patients' cultural background had a strong influence on survival prognoses. Chemotherapy combined with targeted drug therapy could increase the patients' median and overall survival rates. The number of chemotherapy cycles undergone, administration of combined targeted drug therapy, and the cultural backgrounds of the patients had significant effects on the patients' survival prognoses.

The effect of brain metastasis on survival and quality of life of patients with effective treatment of gefitinib

Gefitinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Brain Metastasis

Treatment of Brain Metastasis from Non-Small Cell Lung Cancer with Whole Brain Radiotherapy and Gefitinib in a Chinese Population.

Clinical efficacy of pemetrexed in the treatment of non-small cell lung cancer with asymptomatic brain metastasis

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.

Therapeutic effects of whole brain radiotherapy with targeted therapy and concomitant chemo-radiotherapy in treatment of non-small-cell lung cancer with brain metastasis

Concomitant Treatment of Brain Metastasis from Non-Small Cell Lung Cancer with Whole Brain Radiotherapy and Gefitinib

Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure.

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Analyses of Prognostic Factors in Cases of Non-Small Cell Lung Cancer with Multiple Brain Metastases

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

A real-world study in advanced non-small cell lung cancer with de novo brain metastasis

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer

Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.

Treatment of Nonsmall Cell Lung Cancer Patients with Synchronous Brain Metastasis: an Analysis of 19 Cases

Clinical Study of Whole Brain Radiotherapy Combined with EGFR-TKI for Non-Small Cell Lung Cancer with Brain Metastases

A Meta-analysis on Gefitinib or Erlotinib in treatment of brain metastases from non-small cell lung cancer

Efficacy of Different Therapies for Brain Metastases of Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

Therapeutic effect of 3D conformal radiotherapy for patients with brain metastasis of nonsmall cell lung cancer and their prognosis